Buradasınız

Anasayfa » Content

OCTREOTIDE'NİN YENİDOĞAN STREPTOZOTOCIN DİYABETİK SIÇAN BÖBREĞİ VE IGF-1 DÜZEYLERİ ÜZERİNE ETKİLERİ

Journal Name:

  • Cerrahpaşa Tıp Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
It has been shown by the studies that somatostatin and its analogues (octreotide) have a useful effect on the treatment of diabetes and its complications. In this study 4 groups of newborn Wistar rats were prepared. 1st and 2nd Group; Neonatal STZ (n-STZ)-diabetic group (100 mg/kg, single dose, i.p. on the second day of birth). 2nd Group; Octreotide treated n-STZ-diabetic group ( 200 µg/kg/day, i.p, from 12.week to 18.week ). 3rd Group; Octreotide treated non diabetic group ( 200 µg/kg/day,i.p., from 12.week to 18.week). 4.Group; Control group. In all STZ treated groups (1st ,2nd group) while a significant increase in the blood glucose compared to healty controls until 12th week. Results.- A decrease in the blood glucose levels of octreotide treated diabetic group have been observed. Kidney weights were increased in STZ diabetic groups compared to healty control groups. A significant increase in octreotide treated diabetic groups was determined. Serum IGF-1 levels were found decreased in octreotide treated diabetic group. Glomerule sizes increased in STZ diabetic groups compared to controls. There were basal membrane thickening and significant increase in mesangial matrix and mesangial cells in the diabetic groups. Renal tissue IGF-1 immunoreactivity on the kidney tubules of the control group was found higher than the diabetic group. IGF-1 immunosreactivity was generally seen on the glomerules of the STZ-diabetic group. In Octreotide treated nSTZ-diabetic group weaker IGF-1 immunreaction observed at glomerules and tubules compared to nSTZ-diabetic and healthy control group. The microalbuminuria levels of the treated diabetic group were found reduced when compared with the diabetic group. Conclusion.- We observed that the dose of octreotide and the period has an important contribution for preventation and improvement of nephropathy and prevent the renal tissue damage. on the newborn STZ-diabetic rats.
Bookmark/Search this post with
Abstract (Original Language): 
Somatostatin ve analoglarının (Octreotide- SMS 201-995) diyabet ve komplikasyonlarının tedavisinde yararlı etkiye sahip olduğu çeşitli çalışmalarla bildirilmiştir. Çalışmamızda yenidoğan (YD) Wistar sıçanlardan oluşan 4 grup kullanldı. Doğumun 2. günü (YD:2) 1. ve 2. grup YD-STZ-diyabetik grup (100 mg/kg, tek doz, i.p., doğumun 2. günü), 2.grup; Octreotide tedavili YD-STZ-diyabetik grup (200 µg/kg/ gün, i.p., 12.haftadan itibaren 6 hafta), 3.grup; Octreotide uygulanan diyabetik olmayan grup (200µg/kg/gün, i.p., 12.haftadan itibaren 6 hafta), 4.grup; sağlıklı kontrol olarak ayrıldı. STZ uygulanan gruplarda 12.haftaya kadar sağlıklı kontrole göre kan glukozunda belirgin artış gözlenirken, octreotide uygulanan diyabetik grupta kan glukoz düzeyi düştü. YD-STZdiyabetik grupta böbrek ağırlıklarında sağlıklı kontrol grubuna kıyasla artış saptandı. Octreotide uygulanan diyabetik grupda ise diyabetik gruba kıyasla böbrek ağırlıkları azaldı. STZdiyabetik gruplarda serum IGF-1 düzeylerinin octreotide uygulanan diyabetik grupta düştüğü saptandı. Glomerül boyutlarının YD-STZ-diyabetiklerde sağlıklı kontrole kıyasla arttığı gözlendi. Diyabetik gruplarda bazal membran kal ınlaşması, mezangial matriks ve mezangial hücre artışı gözlendi. Diyabetik grupta glomer üllerde kuvvetli IGF-1 immunpozitifliği gözlendi. Tedavili YD-STZ-diyabetik grupta, diyabetik ve sağlıklı kontrol gruplarına oranla glomerüllerde ve tubüllerde oldukça zayıf IGF- 1 immunpozitifliği, sağlıklı kontrol grubunda tubüllerde IGF-1 pozitif immunreaksiyonu saptand ı. Mikroalbüminüri düzeyi diyabetik gruba kıyasla tedavili diyabetik grupta azaldı. Sonuç olarak; Octreotide uygulamasının YD-STZ-diyabet modelinde diyabetik nefropatinin ilerlemesini yavaşlattığı ve renal doku hasar ını düzelttiği tespit edildi.
FULL TEXT (PDF): 
PDF icon arastirmax-octreotidenin-yenidogan-streptozotocin-diyabetik-sican-bobregi-igf-1-duzeyleri-uzerine-etkileri.pdf
  • 2
117-123
  • Turkish

REFERENCES

References: 

1. Cortes P, Dumler F, Goldman J, Levin NW. Relationship
between renal function and metabolic alterations in early
streptozotocin-ınduced diabetes in rats. Diabetes 1987;
36: 80-87.
2. Tucker BJ, Collins RC, Ziegler MG, Blandz RC.
Disassociation between glomeruler hyperfiltration and
extracellular volume in diabetic rats. Kidney Int 1991;
39: 1176-1183.
3. Cha T, Thara Y, Yamato E, Yoneda H, Ikegami H, Noma
Y, Shima K, Ogihara. Renal handling of glycated
albumin in non-insulin-dependent diabetes mellitus with
nephropathy. Diabetes Res 1991;12:149-156.
4. Hirose K, Qsterby R, Nozawa M, Jorgen H, Gundersen
G. Development of glomerular lesions in experimental
long-term diabetes in the rat. Kidney Int 1982;21:689-
695.
5. Gambaro G, Cavazzana AO, Luzi P, Precoli A, Borsatti
A, Crepaldi G, Marchi E, Venturini AP, Baggio B.
Glycosaminoglycans prevent morphological renal
alterations and albuminuria in diabetic rats. Kidney Int
1992; 42: 285-291.
6. Mogensen CE, Christensen CK. Predicting diabetic
nephropathy in insulin dependet patients. N Eng J Med
1984;311:89-93.
7. Lehmann R, D.Schleicher E. Molecular mechanism of
diabetic nephropathy. Clin. Chim. Acta. 2000; 297: 135-
144.
8. Flyvbjerg A, Frystyk J, Marshall SM. Additive Increase
in kidney insulin-like growth factor 1 and initial renal
enlargement in uninephrectomized-diabetic rats. Horm
Metab Res 1990; 22; 516-520.
9. Flyvbjerg A,Bornfeldt KE, Marshall SM, Arnquist HJ
,Orskov H. Kidney IGF-I mRNA initial renal
hypertrophy in experimental diabetes in rats.
Diabetologia 1990; 33;334-338.
10. Flyvbjerg A. Role of growth hormone, insulin-like
growth factors (IGFs) and IGF-binding proteins in the
renal complications of diabetes.Kidney Int 1997; 52
(suppl 60): S12-S19.
11. Feld S, Hirschberg R. Insulinlike growth factor-I and the
kidney. Trends Endocrinol Metab 1996; 7: 85-93.
12. Hirschberg R. IGF-I and the kidney. J Lab Clin Med
1993; 122: 636-638.
13. Orskov H. Flyvbjerg A, Frystyk J, GrØnbaek H, Foegh
M, Harris AG. IGF-1and acute renal hypertrophy:
inihibition by somatostatin analogues. Transplantation
Proceedings 1993; 25(N2):2061-2062.
14. Karshima T, Schally Aw. Superactive somatostatin
analog decrases plasma glucose and glucagon levels in
diabetic rats. Peptides 1998;9:561-565.
15. Serri O, Beauregard H, Brazeau P, Abribat T, Lambert J.
Harris A, Vachion L. Somatostatin analogue, octreotide,
reduces increased glomerular filration rate and kidney
size in insulin dependet diabetes. JAMA 1991;265 (N7):
888-892.
16. Flyvbjerg A, Marshall SM, Frystyk J, Hansen KW, Harris
AG, Qrskov H. Octreotide administration in diabetic rats:
Effects on renal hypertrophy and urinary albumin
excretion. Kidney Int 1992; 41: 805-812.
17. Flyvbjerg A, Hill C. And Logan A. Pathophsiological
role of growth factors in diabetic kidney disease; focus on
innovative theraphy. ;TEM 1999; 10: 267-272.
18. Altuğ T, Gürel A, İkitimur E, Kuşçu B, Doğruman H,
Yeşildere T, Büyükderim S Sıçanlarda neonatal dönemde
farklı dozlarda streptozotocin uygulanmasının böbrek
kisti ve tümörü oluşturma etkileri. Endokrinolojide
Yönelişler 1996; 6: 136-139.
19. Sounders BD, Trappe RG. Basic & Clinical Biostatics. 2.
ed. Appleton & Lange, London.1994
20. Lee P, Baker B, Liu F, Kwan E, Hintz R. A homologous
radioimmunoassay for rat insulin like growth factor-1
(IGF-1); implications for studies of human IGF-1
physiology. J Clin.Endoc. and Metab 1998;81:2002-
2005.
21. Öztürk M. Işık Mikroskopides İmmünoişaretleme
Yöntemleri. Uygulamalı Ultrastruktürel
İmmunohistokimya Kurs Kitapcığı. Yazarlar:Yılmazer S,
Öztürk M. 6-8 Mayıs 1998, İstanbul.
22. Hammerman MR. New treatments for acute renal failure:
growth factors and beyond. Curr Opin Nephrol
Hypertens1997; 6: 7-9.
23. Rubinger D, Weiss O, Zarfati D, Popovtzer MM, Raz I.
The effect of low dose octreotide administration on renal
function and on gene expression of IGF-1 axis
components in experimental diabetes mellitus. J
Endocrinol 1998;159:133-140.
24. Evan AP, Henry DP, Connors B, Summerlin P, Lee WH.
Analysis of insulin-like growth factors (IGF)-1,and-II,
type II IGF receptor and IGF-binding protein-2 mRNA
and peptide levels in normal and nephrectomized rat
kidney. Kidney Int 1995;48:1517-1519.
25. Parving HH, Andersen AR, Smidt UM, Hommel E,
Mathiesen ER, Svendsen PA. Effect of antihypertensive
treatment on kidney function in diabetic nephropathy
BMJ 1987;294:1443-1447.
26. Öztürk M, Kaya F, Toparlak T, Tunçdemir M, Akkan
AG, Yılmazer S, Şatıroğlu G. The effect of AICAriboside
treatment on pancreatic ß cell in neonatal
streptozotocin induced diabetic rat. 13.Ulusal Elektron
Mikroskopi Kongresi, Bildiriler Kitabı.(1-4 Eylül
1997,ODTÜ-Ankara),s:335-340.
27. Portha B, Blondel O, Serades P, McEvoy R, Grioix MH,
Kergoat M, Bailbe D. The rat models of nonins
ülin dependent diabetes induced by neonatal
streptozotocin. Diabete&Metab 1989;15:61-75.
28. Walker JD, Close CF, Jones SL, Ratfertery M, Keen H,
Vibert G C, Qsterby R. Glomeruler structure in type -1
(õnsulin -dependen -1) diabet patients with normo and
microalbuminuria .Kıdney Int 1992;41:741-749.
29. New JP, Canavan JP, Flyvbjerg A, Haman G, Bilaus
RW, Marsahall JM. Renal enlargement and insulin -like
growth factor-1 accumulation in the wistar rat model of
exprimental diabetes is not prevented by angiotensin
convertin enzyme inhibition. Diabetologia 1996;39:166-
171.
30. Stackhouse S, Miller PL, Park SK, Meyer TW. Reversal
of glomerular hyperfiltration and renal hypertrophy by
blood glucose normalization in diabetic rats .Diabetes
1990;39:989-995.
31. Fervanze FC, Tsao T, Hoffman AR, Rabkin R. Regional
changes in the intrarenal insulin-like growth factor-I axis
in diabetes. Kidney Int 1997;51: 811-818.
32. Rabkin R, Brody M, Lu LK, Chan C, Shaheen Am,
Gillett N. Expression of the genes encoding the rat renal
õnsulin-like growth factor1 system. J Am Nephrol
1995;6:1511-1518.
33. Sugimoto H, Shikata K, Makino H, Ota K, Ota Z.
Increased gene expression of insulin - like growth factor-
1 receptor in experimental diabetic rat glomeruli.
Nephron 1996;72:648-653.
34. Tsao T, Wang J, Fervenza FC, Vu TH, Jin IH, Hoffman
AR, Rabkin R. Renal growth hormone Insulin like
growth factor 1 system in acute renal failure . Kidney Int
1995.;47: 1685 –1668.
35. Miyatake N, Shikata K, Wada J, Sugimoto H, Takahashi
S, Makino H. Differerential distribution of insulin-like
growth factor-1 and insulin-like growth factor binding
proteins in experimental diabetic rat kidney. Nephron
1999;81;317-323.
36. Busiguına S, Chowen JA, Argente J, Torres-Aleman I.
Specific alterations of the insulin-like growth factor 1
system in the cerebellum of diabetic rats. Endocrinology
1996;137:4980-4987.
37. Gronbaek H, Vogel I, Osterby R, Lancrangan I, Flyvbjerg
A, Orskov H. Effect of octreotide, captopril or insülin on
renal changes and UAE in long-term experimental
diabetes. Kidney Int. 1998;53:173-180.
38. Raz I; Rubinger D, Popovtzer M, Gronbeak H, Werss O,
Flyvbjerg A. Octreotide prevents the early ıncrease in
renal ınsulin-like growth fuctor binding protein 1 in
streptozotocin diabetic rats. Diabetes 1998;47:924-930.

Thank you for copying data from http://www.arastirmax.com